Challenges and advancements in the development of vaccines and therapies against Chagas disease

Autores
Pinazo, Maria Jesus; Malchiodi, Emilio Luis; Ioset, Jean Robert; Bivona, Augusto Ernesto; Gollob, Kenneth J.; Dutra, Walderez O.
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, presents a substantial global health burden, affecting millions of individuals worldwide and posing a continual risk of infection. Despite the high mortality and morbidity rates, effective vaccines to prevent infection by the parasite remain elusive, and the drugs currently available are suboptimal. Understanding the intricate dynamics of parasite–host interactions and the resulting immune responses, which contribute to both protection and pathology, is crucial for the development of effective vaccines and therapies against Chagas disease. In this Series paper, we discuss the challenges associated with discovering and translating prophylactic and therapeutic strategies from the laboratory bench to clinical application. We highlight ongoing efforts in vaccine and new drug development, with a focus on more advanced candidates for vaccines and drugs. We also discuss potential solutions, emphasising the importance of collaborative research efforts, sustained funding, and a comprehensive understanding of host–parasite interactions and immunopathology to advance the development of new vaccines and therapies against Chagas disease.
Fil: Pinazo, Maria Jesus. Drugs For Neglected Diseases Initiative; Brasil
Fil: Malchiodi, Emilio Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Ioset, Jean Robert. Drugs For Neglected Diseases Initiative; Suiza
Fil: Bivona, Augusto Ernesto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Gollob, Kenneth J.. Hospital Israelita Albert Einstein; Brasil. Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais; Brasil
Fil: Dutra, Walderez O.. Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais; Brasil. Universidade Federal de Minas Gerais; Brasil
Materia
TRYPANOSOMA CRUZI
CHAGAS DISEASE
VACCINE
BENZNIDAZOLE
VACCINE-LINKED CHEMOTHERAPY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/263449
Acceder
id CONICETDig_7d3542c8862d14d1f8cc0add577f49c5
oai_identifier_str oai:ri.conicet.gov.ar:11336/263449
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Challenges and advancements in the development of vaccines and therapies against Chagas diseasePinazo, Maria JesusMalchiodi, Emilio LuisIoset, Jean RobertBivona, Augusto ErnestoGollob, Kenneth J.Dutra, Walderez O.TRYPANOSOMA CRUZICHAGAS DISEASEVACCINEBENZNIDAZOLEVACCINE-LINKED CHEMOTHERAPYhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, presents a substantial global health burden, affecting millions of individuals worldwide and posing a continual risk of infection. Despite the high mortality and morbidity rates, effective vaccines to prevent infection by the parasite remain elusive, and the drugs currently available are suboptimal. Understanding the intricate dynamics of parasite–host interactions and the resulting immune responses, which contribute to both protection and pathology, is crucial for the development of effective vaccines and therapies against Chagas disease. In this Series paper, we discuss the challenges associated with discovering and translating prophylactic and therapeutic strategies from the laboratory bench to clinical application. We highlight ongoing efforts in vaccine and new drug development, with a focus on more advanced candidates for vaccines and drugs. We also discuss potential solutions, emphasising the importance of collaborative research efforts, sustained funding, and a comprehensive understanding of host–parasite interactions and immunopathology to advance the development of new vaccines and therapies against Chagas disease.Fil: Pinazo, Maria Jesus. Drugs For Neglected Diseases Initiative; BrasilFil: Malchiodi, Emilio Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; ArgentinaFil: Ioset, Jean Robert. Drugs For Neglected Diseases Initiative; SuizaFil: Bivona, Augusto Ernesto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; ArgentinaFil: Gollob, Kenneth J.. Hospital Israelita Albert Einstein; Brasil. Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais; BrasilFil: Dutra, Walderez O.. Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais; Brasil. Universidade Federal de Minas Gerais; BrasilElsevier2024-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/263449Pinazo, Maria Jesus; Malchiodi, Emilio Luis; Ioset, Jean Robert; Bivona, Augusto Ernesto; Gollob, Kenneth J.; et al.; Challenges and advancements in the development of vaccines and therapies against Chagas disease; Elsevier; The Lancet Microbe; 5; 10; 10-2024; 1-122666-5247CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.lanmic.2024.100972info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2666524724002337info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:00:17Zoai:ri.conicet.gov.ar:11336/263449instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:00:18.023CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Challenges and advancements in the development of vaccines and therapies against Chagas disease
title Challenges and advancements in the development of vaccines and therapies against Chagas disease
spellingShingle Challenges and advancements in the development of vaccines and therapies against Chagas disease
Pinazo, Maria Jesus
TRYPANOSOMA CRUZI
CHAGAS DISEASE
VACCINE
BENZNIDAZOLE
VACCINE-LINKED CHEMOTHERAPY
title_short Challenges and advancements in the development of vaccines and therapies against Chagas disease
title_full Challenges and advancements in the development of vaccines and therapies against Chagas disease
title_fullStr Challenges and advancements in the development of vaccines and therapies against Chagas disease
title_full_unstemmed Challenges and advancements in the development of vaccines and therapies against Chagas disease
title_sort Challenges and advancements in the development of vaccines and therapies against Chagas disease
dc.creator.none.fl_str_mv Pinazo, Maria Jesus
Malchiodi, Emilio Luis
Ioset, Jean Robert
Bivona, Augusto Ernesto
Gollob, Kenneth J.
Dutra, Walderez O.
author Pinazo, Maria Jesus
author_facet Pinazo, Maria Jesus
Malchiodi, Emilio Luis
Ioset, Jean Robert
Bivona, Augusto Ernesto
Gollob, Kenneth J.
Dutra, Walderez O.
author_role author
author2 Malchiodi, Emilio Luis
Ioset, Jean Robert
Bivona, Augusto Ernesto
Gollob, Kenneth J.
Dutra, Walderez O.
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv TRYPANOSOMA CRUZI
CHAGAS DISEASE
VACCINE
BENZNIDAZOLE
VACCINE-LINKED CHEMOTHERAPY
topic TRYPANOSOMA CRUZI
CHAGAS DISEASE
VACCINE
BENZNIDAZOLE
VACCINE-LINKED CHEMOTHERAPY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, presents a substantial global health burden, affecting millions of individuals worldwide and posing a continual risk of infection. Despite the high mortality and morbidity rates, effective vaccines to prevent infection by the parasite remain elusive, and the drugs currently available are suboptimal. Understanding the intricate dynamics of parasite–host interactions and the resulting immune responses, which contribute to both protection and pathology, is crucial for the development of effective vaccines and therapies against Chagas disease. In this Series paper, we discuss the challenges associated with discovering and translating prophylactic and therapeutic strategies from the laboratory bench to clinical application. We highlight ongoing efforts in vaccine and new drug development, with a focus on more advanced candidates for vaccines and drugs. We also discuss potential solutions, emphasising the importance of collaborative research efforts, sustained funding, and a comprehensive understanding of host–parasite interactions and immunopathology to advance the development of new vaccines and therapies against Chagas disease.
Fil: Pinazo, Maria Jesus. Drugs For Neglected Diseases Initiative; Brasil
Fil: Malchiodi, Emilio Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Ioset, Jean Robert. Drugs For Neglected Diseases Initiative; Suiza
Fil: Bivona, Augusto Ernesto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Gollob, Kenneth J.. Hospital Israelita Albert Einstein; Brasil. Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais; Brasil
Fil: Dutra, Walderez O.. Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais; Brasil. Universidade Federal de Minas Gerais; Brasil
description Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, presents a substantial global health burden, affecting millions of individuals worldwide and posing a continual risk of infection. Despite the high mortality and morbidity rates, effective vaccines to prevent infection by the parasite remain elusive, and the drugs currently available are suboptimal. Understanding the intricate dynamics of parasite–host interactions and the resulting immune responses, which contribute to both protection and pathology, is crucial for the development of effective vaccines and therapies against Chagas disease. In this Series paper, we discuss the challenges associated with discovering and translating prophylactic and therapeutic strategies from the laboratory bench to clinical application. We highlight ongoing efforts in vaccine and new drug development, with a focus on more advanced candidates for vaccines and drugs. We also discuss potential solutions, emphasising the importance of collaborative research efforts, sustained funding, and a comprehensive understanding of host–parasite interactions and immunopathology to advance the development of new vaccines and therapies against Chagas disease.
publishDate 2024
dc.date.none.fl_str_mv 2024-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/263449
Pinazo, Maria Jesus; Malchiodi, Emilio Luis; Ioset, Jean Robert; Bivona, Augusto Ernesto; Gollob, Kenneth J.; et al.; Challenges and advancements in the development of vaccines and therapies against Chagas disease; Elsevier; The Lancet Microbe; 5; 10; 10-2024; 1-12
2666-5247
CONICET Digital
CONICET
url http://hdl.handle.net/11336/263449
identifier_str_mv Pinazo, Maria Jesus; Malchiodi, Emilio Luis; Ioset, Jean Robert; Bivona, Augusto Ernesto; Gollob, Kenneth J.; et al.; Challenges and advancements in the development of vaccines and therapies against Chagas disease; Elsevier; The Lancet Microbe; 5; 10; 10-2024; 1-12
2666-5247
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.lanmic.2024.100972
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S2666524724002337
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613782859415552
score 13.070432

Publicaciones similares